VEGF Contributes to Mesenchymal Stem Cell-Mediated Reversion of Nor1-Dependent Hypertrophy in iPS Cell-Derived Cardiomyocytes
Myocardial hypertrophy is present in many heart diseases, representing a strong predictor of adverse cardiovascular outcomes. Regarding therapeutic intervention, mesenchymal stem cells (MSCs) have been suggested to significantly reduce cardiac hypertrophy and progression to heart failure. Preconditi...
Saved in:
| Main Authors: | Denise Philipp, Michelle Holthaus, Vida Basoah, Kurt Pfannkuche, Laura Suhr, Thorsten Wahlers, Adnana Paunel-Görgülü |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2021/8888575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retention of locally injected human iPS cell-derived cardiomyocytes into the myocardium using hydrolyzed gelatin
by: Jun Iida, et al.
Published: (2025-02-01) -
Allogenic mitochondria transfer improves cardiac function in iPS-cell-differentiated cardiomyocytes of a patient with Barth syndrome
by: Ye Seul Kim, et al.
Published: (2025-06-01) -
The Potential of iPS Cells in Synucleinopathy Research
by: Leonhard Linta, et al.
Published: (2012-01-01) -
Effect of mechanical stretching stimulation on maturation of human iPS cell-derived cardiomyocytes co-cultured with human gingival fibroblasts
by: Mengxue Wang, et al.
Published: (2025-08-01) -
Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
by: Shota Yanagida, et al.
Published: (2025-08-01)